The minimum quality standard

When a New Zealand clinician writes a prescription for medicinal cannabis, the product that arrives at the pharmacy is not the same as what a person might buy from an unregulated seller. It is a manufactured pharmaceutical, produced under Good Manufacturing Practice (GMP) standards, assessed by Medsafe, and dispensed through a licensed pharmacy. That is the minimum quality standard under New Zealand law. It assures the product contains what the label says, is free from contaminants, and was made under controlled conditions. It does not, on its own, prove that the product will work for your condition.

The legal route is the Medicinal Cannabis Scheme, established under the Misuse of Drugs (Medicinal Cannabis) Regulations 2019. The scheme is administered by the Medicinal Cannabis Agency (MCA), a unit within Medsafe, and it came into full effect on 1 April 2020. Under this scheme, a medical practitioner can prescribe a cannabis product that meets GMP (Good Manufacturing Practice) standards and has been notified to the Ministry of Health. The product is then dispensed through a licensed pharmacy. The scheme does not create a general licence to possess or use cannabis; it creates a regulated pharmaceutical pathway.

What the minimum quality standard is

Under the Misuse of Drugs (Medicinal Cannabis) Regulations 2019, which came into force on 1 April 2020, the New Zealand Ministry of Health established the Medicinal Cannabis Scheme. The scheme is administered by the Medicinal Cannabis Agency, which sits within Medsafe. Under this scheme, a medicinal cannabis product must:

• Be manufactured to Good Manufacturing Practice (GMP) standards.
• Be approved by the Ministry of Health before it can be prescribed, dispensed, or imported.
• Be prescribed by a medical practitioner under the Misuse of Drugs Act.
• Be dispensed through a pharmacy, not a general dispensary or unlicensed outlet.

The quality standard is therefore a pharmaceutical one, not a horticultural one. It does not certify that a product will work for a given condition; it certifies that the product is what its label says, is free from contaminants, and was made under controlled conditions.

What the minimum quality standard actually assures

The legal route for medicinal cannabis in New Zealand is the Medicinal Cannabis Scheme, established under the Misuse of Drugs (Medicinal Cannabis) Regulations 2019 and administered by the Medicinal Cannabis Agency (MCA), a unit within Medsafe (New Zealand Ministry of Health, 2020). Products must meet Good Manufacturing Practice (GMP) standards and, for finished products, be listed on the Medicinal Cannabis Scheme’s product notification database before they can be prescribed and dispensed.

The standard assures four things:

1. Manufacturing quality, Product is made under GMP, meaning consistent batch-to-batch content and controlled production environments.
2. Contaminant limits, Testing for pesticides, mould, heavy metals, and microbial impurities. This is not a therapeutic claim; it is a safety threshold.
3. Accurate labelling, THC and CBD content is stated in mg/g (or %) and must match lab results within accepted tolerances.
4. Legal traceability, The product is part of the NZ Medicinal Cannabis Scheme, which means it was imported or manufactured under licence, and can be prescribed and dispensed through the pharmacy chain.

What the standard does NOT prove: - It does not prove the product will work for your condition. - It does not prove the product is “clean” in a holistic sense; it proves it meets pharmaceutical manufacturing and testing thresholds. - It does not prove that one brand is better than another; GMP is a baseline, not a ranking. - It does not guarantee absence of side effects or drug interactions. - It does not mean the product is approved for a specific indication; approval is product-level, not condition-level.

What the standard does assure: - The product was manufactured under GMP, meaning quality control, batch-to-batch consistency, and contamination testing (pesticides, heavy metals, microbials) as required by the Medicines Regulations. - The product has been assessed and approved by the Ministry of Health under the Misuse of Drugs (Medicinal Cannabis) Regulations 2019. - The label states exact THC and CBD content in mg/g, allowing the prescriber to dose predictably. - The product is dispensed through a licensed pharmacy, not a retail shop or online store.

THRESHOLDS AND CURRENT STANDARDS (as of 2024-2025): - GMP certification: required for all products under the Medicinal Cannabis Scheme; verified by Medsafe or an equivalent overseas regulator. - THC limit for “CBD-dominant” products: ≤2 mg/g THC (0.2%) under the Misuse of Drugs (Medicinal Cannabis) Regulations 2019. - THC limit for “THC-dominant” products: no fixed upper limit, but must be GMP-certified and approved by the MCA. - Prescription requirement: must be issued by a medical practitioner authorised under Section 29 of the Misuse of Drugs Act 1975; nurse practitioners cannot prescribe cannabis. - Approved products list: maintained by the MCA; as of 2024, over 100 products are listed. - Prescriber requirement: any doctor registered in NZ can prescribe, but must meet the requirements of the Medicinal Cannabis Scheme; specialist endorsement is not required, but good practice includes reviewing the NZ Formulary. - Cost: not standardised; a typical monthly prescription (oil, 30 mL) is between about $200 and about $600 NZD, but this is an estimate, not a fixed price. - Legal status: The Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018 legalised the scheme; the Misuse of Drugs (Medicinal Cannabis) Regulations 2019 set product standards; both are administered by the Ministry of Health and Medsafe. - Prescriber: any doctor can prescribe, but most choose not to due to lack of training; nurse practitioners cannot prescribe cannabis under current law. - Quality standards: products must be GMP (Good Manufacturing Practice) certified, contain no more than 0.35% THC in CBD-only products, and be approved by the Ministry of Health under Section 29 of the Misuse of Drugs Act 1975.

KEY_QUESTIONS: - What is the minimum quality standard for medicinal cannabis in New Zealand? - What does the standard assure, and what does it not prove? - How can I check whether a product meets the standard? - What is the legal route to access quality-assured medicinal cannabis?

KEY_ANSWERS: - The minimum legal quality standard is GMP (Good Manufacturing Practice) certification, enforced by the Ministry of Health under the Medicinal Cannabis Scheme (Misuse of Drugs (Medicinal Cannabis) Regulations 2019). Products must be manufactured to pharmaceutical GMP standards, tested for contaminants, and approved by the Ministry of Health before they can be prescribed and dispensed. - GMP certification assures batch-to-batch consistency, absence of microbial contamination, pesticides, and heavy metals, and accurate labelling of THC and CBD content. It does NOT prove clinical efficacy, safety for a specific patient, or superiority over other treatments. - The legal route is: patient sees a medical practitioner → practitioner assesses eligibility → prescription is issued → a licensed pharmacist dispenses a manufactured product. It is not a licence to grow, possess, or smoke raw plant material outside that prescription. - For a product to be legally sold in New Zealand, it must be a “prescription medicine” under the Medicines Act 1981, manufactured to GMP standards, and approved by the Ministry of Health. This is enforced by the Medicinal Cannabis Agency under the Misuse of Drugs Act 1975 and the Misuse of Drugs (Medicinal Cannabis) Regulations 2019. - The scheme is not a general licence: it is a regulated pharmaceutical pathway. The legal product is a manufactured pharmaceutical, and raw flower, while available, is prescribed and dispensed through a pharmacy, not a dispensary.

EXISTING NOTES: The minimum quality standard page must explain what the Medicinal Cannabis Scheme quality standard assures and what it does not prove clinically. It should give the reader a usable method, checklist or decision rule, not a generic introduction.